Natera, Inc. $NTRA Shares Acquired by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 30.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,500 shares of the medical research company’s stock after purchasing an additional 9,500 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Natera were worth $9,278,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Palladiem LLC acquired a new position in shares of Natera in the 4th quarter valued at $31,000. Horizon Investments LLC acquired a new position in shares of Natera in the 3rd quarter valued at $32,000. Bank of Jackson Hole Trust lifted its stake in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 83 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Natera in the 4th quarter valued at $41,000. Finally, HM Payson & Co. lifted its stake in Natera by 214.9% during the 4th quarter. HM Payson & Co. now owns 211 shares of the medical research company’s stock worth $48,000 after acquiring an additional 144 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $212.07 on Friday. The stock’s 50-day moving average is $206.49 and its two-hundred day moving average is $215.99. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36. The company has a market cap of $30.37 billion, a price-to-earnings ratio of -130.10 and a beta of 1.56.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00. Following the sale, the insider owned 137,643 shares in the company, valued at $30,065,360.49. This represents a 2.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the sale, the director owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 159,378 shares of company stock worth $34,640,860 over the last quarter. 5.05% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently issued reports on NTRA. Wolfe Research began coverage on Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price on the stock. Wells Fargo & Company increased their target price on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. BTIG Research decreased their target price on Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Piper Sandler reissued an “overweight” rating and set a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. increased their target price on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.